Aptuit Appoints New CEO
Aptuit appoints Jonathan Goldman as CEO.
Aptuit, a provider of outsourced services in the early development space, has appointed Jonathan Goldman, MD, as the company’s new CEO. Goldman joins the company after working at ICON Clinical Research.
Goldman was most recently executive vice president, global strategic and business development at ICON and a member of the senior leadership team. Previously, his roles at ICON included executive VP, operations, strategic programs and chief medical officer, ICON Medical Imaging.
Before joining ICON, Goldman served for seven years as the chief medical officer of POINT Biomedical, a US-based biopharmaceutical company that discovered and developed microsphere technologies and drugs. In addition, he has held academic positions at the University of California since 2000, most recently as associate clinical professor of medicine in the Division of Cardiology.
Source: Aptuit
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
